Literature DB >> 17322463

Adalimumab in the therapy of uveitis in childhood.

Ahmad M Mansour.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17322463      PMCID： PMC1857669          DOI： 10.1136/bjo.2006.108050

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  19 in total

1.  Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis.

Authors:  Michael F Bullano; Brian J McNeeley; Yanni F Yu; Ralph Quimbo; Lauren P Burawski; Elaine B Yu; J Michael Woolley
Journal:  Manag Care Interface       Date:  2006-09

2.  Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.

Authors:  Kenneth B Gordon; Richard G Langley; Craig Leonardi; Darryl Toth; M Alan Menter; Sewon Kang; Michael Heffernan; Bruce Miller; Regina Hamlin; Liberata Lim; Jianhua Zhong; Rebecca Hoffman; Martin M Okun
Journal:  J Am Acad Dermatol       Date:  2006-08-10       Impact factor: 11.527

3.  Adalimumab therapy for childhood uveitis.

Authors:  Liza B Vazquez-Cobian; Thomas Flynn; Thomas J A Lehman
Journal:  J Pediatr       Date:  2006-10       Impact factor: 4.406

4.  Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis.

Authors:  Leila I Kump; René A Cervantes Castañeda; Sofia N Androudi; George F Reed; C Stephen Foster
Journal:  Ophthalmology       Date:  2006-08-01       Impact factor: 12.079

5.  Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.

Authors:  Anat Galor; Victor L Perez; Jeffrey P Hammel; Careen Y Lowder
Journal:  Ophthalmology       Date:  2006-09-25       Impact factor: 12.079

6.  Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists.

Authors:  Khalid M Kamal; S Suresh Madhavan; Jo Ann Allen Hornsby; Lesley-Ann Miller; Jan Kavookjian; Virginia Scott
Journal:  Joint Bone Spine       Date:  2006-08-28       Impact factor: 4.929

7.  Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study.

Authors:  S Guignard; L Gossec; C Salliot; A Ruyssen-Witrand; M Luc; M Duclos; M Dougados
Journal:  Ann Rheum Dis       Date:  2006-08-10       Impact factor: 19.103

8.  Anti-TNF therapies in the management of acute and chronic uveitis.

Authors:  Sarah Hale; Sue Lightman
Journal:  Cytokine       Date:  2006-03-15       Impact factor: 3.861

9.  Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.

Authors:  R K Saurenmann; A V Levin; J B Rose; S Parker; T Rabinovitch; P N Tyrrell; B M Feldman; R M Laxer; R Schneider; E D Silverman
Journal:  Rheumatology (Oxford)       Date:  2006-02-03       Impact factor: 7.580

10.  Adalimumab-associated optic neuritis.

Authors:  Jacob H Chung; Gregory P Van Stavern; Larry P Frohman; Roger E Turbin
Journal:  J Neurol Sci       Date:  2006-03-09       Impact factor: 3.181
View more
  8 in total

Review 1.  The Use of Biologic Therapies in Uveitis.

Authors:  Sergio Schwartzman; Monica Schwartzman
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 8.667

Review 2.  Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis.

Authors:  William D Renton; Jennifer Jung; Alan G Palestine
Journal:  Cochrane Database Syst Rev       Date:  2022-10-14

3.  Analysis of molecular and clinical parameters of 4-year adalimumab therapy in psoriatic patients.

Authors:  Dominika Wcisło-Dziadecka; Beniamin Grabarek; Celina Kruszniewska-Rajs; Andrzej Swinarew; Krzysztof Jasik; Beata Rozwadowska; Agata Krawczyk
Journal:  Postepy Dermatol Alergol       Date:  2020-11-07       Impact factor: 1.837

4.  Pediatric uveitis.

Authors:  Ilknur Tugal-Tutkun
Journal:  J Ophthalmic Vis Res       Date:  2011-10

5.  Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis.

Authors:  Carmen García-De-Vicuña; Manuel Díaz-Llopis; David Salom; Rosa Bou; Jesus Díaz-Cascajosa; Miguel Cordero-Coma; Gabriela Ortega; Norberto Ortego-Centeno; Marta Suarez-De-Figueroa; Juan Cruz-Martínez; Alex Fonollosa; Ricardo Blanco; Ángel María García-Aparicio; Jose M Benítez-Del-Castillo; Jordi Antón
Journal:  Mediators Inflamm       Date:  2013-12-30       Impact factor: 4.711

Review 6.  Review of Systemic Immunosuppression for Autoimmune Uveitis.

Authors:  Claudia Castiblanco; C Stephen Foster
Journal:  Ophthalmol Ther       Date:  2014-03-18

7.  Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis.

Authors:  Gabriele Simonini; Andrea Taddio; Marco Cattalini; Roberto Caputo; Cinzia de Libero; Fulvio Parentin; Ilaria Pagnini; Loredana Lepore; Rolando Cimaz
Journal:  Pediatr Rheumatol Online J       Date:  2013-04-15       Impact factor: 3.054

8.  Retinal function and morphology in the rabbit eye after intravitreal injection of the TNF alpha inhibitor adalimumab.

Authors:  Anna Cardiakidis Myers; Fredrik Ghosh; Sten Andréasson; Vesna Ponjavic
Journal:  Curr Eye Res       Date:  2014-06-04       Impact factor: 2.424
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.